Financial Results for the First Quarter of
Fiscal Year Ending March 31, 2021 (FY2020)

from the beginning

Financial Results for the First Quarter of Fiscal Year Ending March 31, 2021 (FY2020)

• Despite The COVID-19 Impact on Cardiac & Vascular, The Overall Impact Was Mitigated by Other Companies

• Adjusted Operating Profit Variance Analysis

• Revenue by Region

• Revenue by Business Segment

• Cardiac and Vascular: The COVID-19 Impact Was within the Assumed Range

• General Hospital: Maintained Profitability by Expense Control

• Blood and Cell Technologies: Increase in Both Revenue and Profit

• Major Topics in FY20 Q1

• FY20 New Product Pipeline

• Key Assumptions of FY20 Guidance

• FY20 Guidance(1)

• FY20 Guidance(2)

• FY20 Guidance: Quarterly Trend of the Revenue

Reference

• FY20Q1 Revenue and Growth by Region

• Operating Expenses

• Quarterly Results

• Adjusted Operating Profit: Adjustments

• CAPEX, Depreciation and R&D Expenses

• Cash Flows

• Foreign Exchange Sensitivity

• The Status of Convertible Bonds

IR Contact